title: Cellular effects of HER3-specific affibody molecules.
abstract: Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key player in cancer, and consequently this receptor has gained increased interest as a target for cancer therapy. We have previously generated several Affibody molecules with subnanomolar affinity for the HER3 receptor. Here, we investigate the effects of two of these HER3-specific Affibody molecules, Z05416 and Z05417, on different HER3-overexpressing cancer cell lines. Using flow cytometry and confocal microscopy, the Affibody molecules were shown to bind to HER3 on three different cell lines. Furthermore, the receptor binding of the natural ligand heregulin (HRG) was blocked by addition of Affibody molecules. In addition, both molecules suppressed HRG-induced HER3 and HER2 phosphorylation in MCF-7 cells, as well as HER3 phosphorylation in constantly HER2-activated SKBR-3 cells. Importantly, Western blot analysis also revealed that HRG-induced downstream signalling through the Ras-MAPK pathway as well as the PI3K-Akt pathway was blocked by the Affibody molecules. Finally, in an in vitro proliferation assay, the two Affibody molecules demonstrated complete inhibition of HRG-induced cancer cell growth. Taken together, our findings demonstrate that Z05416 and Z05417 exert an anti-proliferative effect on two breast cancer cell lines by inhibiting HRG-induced phosphorylation of HER3, suggesting that the Affibody molecules are promising candidates for future HER3-targeted cancer therapy.
authors: Department of Radiology, Oncology and Radiation Science, Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden.
authors: Lovisa
authors: L
authors: Göstring
authors: Magdalena
authors: M
authors: Malm
authors: Ingmarie
authors: I
authors: Höidén-Guthenberg
authors: Fredrik Y
authors: FY
authors: Frejd
authors: Stefan
authors: S
authors: Ståhl
authors: John
authors: J
authors: Löfblom
authors: Lars
authors: L
authors: Gedda
mesh_terms: D001667:Binding, Competitive; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004797:Enzyme-Linked Immunosorbent Assay; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D008024:Ligands; D018613:Microscopy, Confocal; D020890:Neuregulin-1 / Q000378:metabolism; D010766:Phosphorylation; D011485:Protein Binding; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D020893:Receptor, ErbB-3 / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000378:metabolism*
chemical_list: D008024:Ligands; D020890:Neuregulin-1; D011956:Receptors, Cell Surface; D011993:Recombinant Fusion Proteins; D020893:Receptor, ErbB-3; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases